Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PTCT PTC Therapeutics, Inc. weekly Stock Chart
PTCT [NASD]
PTC Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-4.87 Insider Own0.50% Shs Outstand62.39M Perf Week1.29%
Market Cap3.15B Forward P/E- EPS next Y-2.30 Insider Trans-54.15% Shs Float60.82M Perf Month6.15%
Income-292.20M PEG- EPS next Q-1.29 Inst Own99.32% Short Float7.34% Perf Quarter-1.77%
Sales321.70M P/S9.80 EPS this Y-55.40% Inst Trans5.36% Short Ratio5.33 Perf Half Y8.50%
Book/sh8.47 P/B6.02 EPS next Y56.50% ROA-19.10% Target Price59.20 Perf Year27.53%
Cash/sh9.63 P/C5.29 EPS next 5Y-9.51% ROE-51.40% 52W Range30.79 - 59.89 Perf YTD6.08%
Dividend- P/FCF- EPS past 5Y-7.50% ROI-27.80% 52W High-13.76% Beta1.45
Dividend %- Quick Ratio3.10 Sales past 5Y64.80% Gross Margin95.70% 52W Low67.74% ATR2.46
Employees754 Current Ratio3.20 Sales Q/Q27.40% Oper. Margin-82.40% RSI (14)59.75 Volatility4.00% 5.10%
OptionableYes Debt/Eq0.60 EPS Q/Q-39.90% Profit Margin-90.80% Rel Volume1.22 Prev Close50.95
ShortableYes LT Debt/Eq0.56 EarningsApr 30 AMC Payout- Avg Volume837.73K Price51.65
Recom2.00 SMA206.19% SMA508.72% SMA20012.00% Volume103,076 Change1.37%
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Jan-29-18Resumed RBC Capital Mkts Sector Perform
Nov-16-17Upgrade JP Morgan Underweight → Neutral
Oct-26-17Downgrade BofA/Merrill Neutral → Underperform
Oct-09-17Downgrade JP Morgan Neutral → Underweight
Sep-29-17Reiterated RBC Capital Mkts Sector Perform
Sep-29-17Reiterated Barclays Equal Weight $22 → $15
Aug-23-17Initiated William Blair Mkt Perform
Mar-16-17Reiterated RBC Capital Mkts Sector Perform $13 → $10
Mar-03-17Downgrade Barclays Overweight → Equal Weight $20 → $13
Jun-01-20 08:00AM  
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
PR Newswire
May-28-20 09:00AM  
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform
PR Newswire
May-27-20 07:04PM  
PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders
PR Newswire
May-26-20 08:00AM  
PTC Therapeutics to Present at the Jefferies Virtual Healthcare Conference
PR Newswire
May-21-20 04:27PM  
PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily
01:10AM  
Edited Transcript of PTCT earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents
May-15-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire +6.15%
May-06-20 04:30PM  
PTC Therapeutics to Acquire Censa Pharmaceuticals
PR Newswire
May-05-20 08:00AM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
Apr-30-20 06:35PM  
PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
Zacks
Apr-28-20 01:00AM  
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
PR Newswire
Apr-23-20 12:32PM  
Earnings Preview: PTC Therapeutics (PTCT) Q1 Earnings Expected to Decline
Zacks
Apr-22-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Apr-17-20 08:00AM  
PTC Therapeutics Announces New Leadership Appointments
PR Newswire
Apr-16-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results
PR Newswire
Apr-09-20 10:16AM  
Does Therapeutics (NASDAQ:PTCT) Have A Healthy Balance Sheet?
Simply Wall St.
Apr-07-20 04:05PM  
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
PR Newswire
Mar-30-20 06:06PM  
FDA Decisions on 5 Drugs Expected in 2nd Quarter
GuruFocus.com +5.45%
Mar-29-20 12:32PM  
Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?
Insider Monkey
Mar-25-20 09:04AM  
Edited Transcript of PTCT earnings conference call or presentation 2-Mar-20 9:30pm GMT
Thomson Reuters StreetEvents
Mar-16-20 08:00AM  
PTC Therapeutics Announces Management Change
PR Newswire -26.33%
Mar-11-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire -8.32%
Mar-10-20 11:53AM  
The Surprising Impact Coronavirus Will Have On Biotech Companies
Investor's Business Daily
Mar-04-20 09:40AM  
Earnings Update: PTC Therapeutics, Inc. Just Reported And Analysts Are Trimming Their Forecasts
Simply Wall St. +9.33%
Mar-02-20 05:25PM  
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update
PR Newswire
Feb-25-20 04:30PM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
Feb-24-20 12:30PM  
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Zacks
Feb-18-20 08:00AM  
PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy
PR Newswire
Feb-17-20 04:30PM  
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
PR Newswire
Feb-06-20 04:08PM  
This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run
Investor's Business Daily
10:41AM  
Is PTC Therapeutics, Inc. (NASDAQ:PTCT) A Volatile Stock?
Simply Wall St.
05:00AM  
SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy
PR Newswire
Feb-03-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
08:05AM  
PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference
PR Newswire
08:00AM  
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
PR Newswire
Jan-23-20 08:51AM  
Roche's Risdiplam Meets Primary Endpoint in Infants Study
Zacks
01:00AM  
Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy
PR Newswire
Jan-13-20 08:00AM  
PTC Therapeutics Provides Corporate Update and Highlights Pipeline Progress at 2020 J.P. Morgan Healthcare Conference
PR Newswire
Jan-07-20 12:09PM  
Why PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Matters To You
Simply Wall St.
Jan-06-20 08:00AM  
PTC Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-26-19 11:58AM  
Hedge Fund Favorites vs. PTC Therapeutics, Inc. (PTCT) In 2019
Insider Monkey
Dec-19-19 10:09AM  
4 Drug/Biotech Outperformers That May Lose Steam in 2020
Zacks
Dec-13-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Dec-04-19 10:23PM  
Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
Insider Monkey
Dec-03-19 10:09AM  
The Therapeutics (NASDAQ:PTCT) Share Price Is Up 289% And Shareholders Are Boasting About It
Simply Wall St.
Nov-29-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Nov-25-19 04:59PM  
Roche's NDA for SMA Drug Risdiplam Gets Priority Review
Zacks
Nov-21-19 11:22AM  
Credit Suisse: 3 Strong Buy Stocks That Are Poised to Beat the Market
TipRanks
Nov-19-19 08:00AM  
PTC Therapeutics to Present at the Evercore ISI 2nd Annual HealthCONx Conference
PR Newswire
Nov-18-19 08:00AM  
PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification
PR Newswire
Nov-12-19 09:43AM  
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study
Zacks
Nov-11-19 01:00AM  
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
PR Newswire
Nov-04-19 11:42PM  
Edited Transcript of PTCT earnings conference call or presentation 29-Oct-19 8:30pm GMT
Thomson Reuters StreetEvents
Oct-31-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Oct-29-19 06:55PM  
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
PR Newswire
Oct-24-19 12:26PM  
When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable?
Simply Wall St.
08:00AM  
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
PR Newswire
Oct-23-19 06:45PM  
Is PTC Therapeutics, Inc. (PTCT) A Good Stock To Buy ?
Insider Monkey
04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Oct-15-19 08:31AM  
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results
PR Newswire
Oct-07-19 08:00AM  
PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing
PR Newswire
Oct-04-19 08:00AM  
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
PR Newswire
Oct-02-19 08:00AM  
Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress
PR Newswire +5.65%
Sep-27-19 08:00AM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
Sep-20-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Sep-18-19 11:34AM  
Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?
Simply Wall St. -11.29%
08:25AM  
PTC Therapeutics Announces Pricing of Private Offering of Convertible Senior Notes
PR Newswire
08:24AM  
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
PR Newswire
Sep-17-19 04:01PM  
PTC Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire
04:01PM  
PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
PR Newswire
Sep-11-19 03:03PM  
Edited Transcript of PTCT earnings conference call or presentation 6-Aug-19 8:30pm GMT
Thomson Reuters StreetEvents
Sep-06-19 08:00AM  
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners
PR Newswire
Aug-19-19 10:51AM  
Does PTC Therapeutics, Inc. (NASDAQ:PTCT) Have A Volatile Share Price?
Simply Wall St.
Aug-07-19 02:24AM  
PTC Therapeutics (PTCT) Q2 2019 Earnings Call Transcript
Motley Fool
Aug-06-19 06:25PM  
PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
PR Newswire
Aug-05-19 08:00AM  
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
PR Newswire
Jul-31-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Jul-30-19 10:38AM  
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
Jul-23-19 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results
PR Newswire
Jul-19-19 08:09AM  
Should You Worry About PTC Therapeutics, Inc.'s (NASDAQ:PTCT) CEO Pay Cheque?
Simply Wall St.
Jul-10-19 05:41PM  
5 Health Care Stocks in Gurus' Portfolios
GuruFocus.com
Jul-01-19 09:21AM  
Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
Zacks
08:00AM  
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
PR Newswire
Jun-28-19 06:40AM  
PTC Provides Update on Translarna (ataluren) Application for Label Expansion
PR Newswire
Jun-14-19 01:49PM  
Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?
Simply Wall St.
Jun-13-19 09:44AM  
Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
Insider Monkey
Jun-07-19 03:02PM  
PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients
Benzinga
01:31PM  
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age
PR Newswire
Jun-03-19 08:00AM  
PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
PR Newswire
May-31-19 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
May-30-19 08:00AM  
PTC Therapeutics to Participate at Upcoming Investor Conference
PR Newswire
May-20-19 08:00AM  
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PR Newswire
May-09-19 04:05PM  
PTC Therapeutics and MRI Interventions Announce Strategic Investment
PR Newswire
May-08-19 04:12PM  
Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT
Thomson Reuters StreetEvents +7.89%
08:00AM  
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire
May-07-19 04:33PM  
This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen
Investor's Business Daily
01:00AM  
Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
PR Newswire
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Peltz Stuart WalterChief Executive OfficerMay 20Option Exercise10.8533,788366,60089,873May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 20Sale50.0033,7881,689,40056,085May 22 04:05 PM
Peltz Stuart WalterChief Executive OfficerMay 18Option Exercise10.856,28468,18162,369May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 18Sale50.126,284314,97956,085May 20 04:07 PM
Peltz Stuart WalterChief Executive OfficerMay 05Option Exercise10.85109,9281,192,719166,013May 07 03:44 PM
Peltz Stuart WalterChief Executive OfficerMay 05Sale50.34109,9285,533,59256,085May 07 03:44 PM
Jacobson Allan StevenDirectorApr 20Option Exercise10.8517,900194,21526,398Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 20Sale51.0417,900913,5588,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Option Exercise18.012,14538,63111,449Apr 21 04:15 PM
Jacobson Allan StevenDirectorApr 17Option Exercise10.852,10022,78510,598Apr 21 04:13 PM
Jacobson Allan StevenDirectorApr 17Sale50.162,100105,3328,498Apr 21 04:13 PM
Utter Christine MarieSVP, Finance & CAOApr 17Sale50.002,145107,2509,304Apr 21 04:15 PM
Utter Christine MarieSVP, Finance & CAOApr 03Option Exercise11.237878,83810,091Apr 07 04:05 PM
Utter Christine MarieSVP, Finance & CAOApr 03Sale44.3178734,8729,304Apr 07 04:05 PM
SCHMERTZLER MICHAELDirectorMar 16Buy32.4810,000324,846100,066Mar 18 05:05 PM
Souza MarcioChief Operating OfficerFeb 10Option Exercise12.926258,0757,369Feb 12 04:09 PM
Souza MarcioChief Operating OfficerFeb 10Sale53.9262533,7006,744Feb 12 04:09 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Option Exercise10.8550,000542,50073,987Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.004,040222,2001,912Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 06Sale55.0050,0002,750,00027,089Feb 07 04:41 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 05Sale55.0040522,2755,952Feb 07 04:41 PM
Hill Emily LuisaChief Financial OfficerJan 23Sale53.2533017,5726,891Jan 27 04:14 PM
Peltz Stuart WalterChief Executive OfficerJan 23Sale53.2542322,52318,102Jan 27 04:12 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 23Sale53.25462,4495,987Jan 27 04:09 PM
Souza MarcioChief Operating OfficerJan 23Sale53.251548,2005,074Jan 27 04:15 PM
Utter Christine MarieSVP, Finance & CAOJan 07Option Exercise15.7813,750216,95012,724Jan 08 06:07 PM
Hill Emily LuisaChief Financial OfficerJan 07Sale49.62633,1267,221Jan 08 06:03 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale49.62592,9286,033Jan 08 06:06 PM
Utter Christine MarieSVP, Finance & CAOJan 07Sale50.0213,750687,7335,224Jan 08 06:07 PM
Souza MarcioChief Operating OfficerJan 06Sale48.17864,1425,228Jan 08 06:09 PM
Utter Christine MarieSVP, Finance & CAOJan 06Sale48.1736017,3405,224Jan 08 06:07 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.171276,1176,092Jan 08 06:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 06Sale48.1750724,42116,889Jan 08 06:06 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.1779838,43818,525Jan 08 06:04 PM
Peltz Stuart WalterChief Executive OfficerJan 06Sale48.171,79786,55823,085Jan 08 06:04 PM
Hill Emily LuisaChief Financial OfficerJan 06Sale48.1732115,4627,284Jan 08 06:03 PM
Utter Christine MarieSVP, Finance & CAOJan 03Option Exercise11.237888,8496,372Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 03Sale47.4278837,3675,584Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Option Exercise11.232,36226,5257,946Jan 06 04:52 PM
Utter Christine MarieSVP, Finance & CAOJan 02Sale47.892,362113,1115,584Jan 06 04:52 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise12.926,25080,75011,288Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Option Exercise14.4275,8811,094,54468,221Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.806,250305,0005,038Dec 26 05:24 PM
Souza MarcioChief Operating OfficerDec 23Sale48.9096,6954,728,73238,221Dec 26 05:24 PM
Peltz Stuart WalterChief Executive OfficerDec 03Option Exercise13.9718,981265,16926,332Dec 05 04:50 PM
Peltz Stuart WalterChief Executive OfficerDec 03Sale50.0022,4631,123,15018,676Dec 05 04:50 PM
Boulding Mark ElliottExec. VP and CLOJul 05Option Exercise15.1015,312231,27933,899Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 05Sale44.7415,312685,09729,524Jul 09 04:54 PM
Boulding Mark ElliottExec. VP and CLOJul 01Option Exercise24.23104,0922,521,639100,373Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJul 01Option Exercise20.8113,071271,96814,234Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJul 01Sale45.1513,071590,1434,937Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJul 01Sale45.00104,0924,684,14029,524Jul 02 06:46 PM
Boulding Mark ElliottExec. VP and CLOJun 28Option Exercise11.3577,575880,72373,614Jul 02 06:46 PM
Utter Christine MarieSVP, Finance & CAOJun 28Option Exercise20.8198820,5575,640Jul 02 09:40 PM
Utter Christine MarieSVP, Finance & CAOJun 28Sale45.0098844,4604,937Jul 02 09:40 PM
Boulding Mark ElliottExec. VP and CLOJun 28Sale45.0077,5753,490,87529,524Jul 02 06:46 PM
open in yahoo | open in reuters | open in google